BENJAMIN SAXEY: Open Payments
NPI 1225482201 · LAYTON, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,644 in 90 payments from 17 companies in 2025. Trend: 2023 $1,282 · 2024 $1,440 · 2025 $1,644
Food & beverage: $1,644
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 13 | $287 |
| Teva Pharmaceuticals USA, Inc. | 14 | $206 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $202 |
| Neurocrine BioSciences, Inc. | 8 | $164 |
| ABBVIE INC. | 13 | $163 |
| Janssen Pharmaceuticals, Inc | 8 | $144 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $127 |
| Axsome Therapeutics, Inc. | 5 | $92 |
| Alkermes, Inc. | 4 | $78 |
| Biogen, Inc. | 2 | $39 |
Products named: FANAPT, CAPLYTA, INGREZZA, VRAYLAR, AUSTEDO XR, TRINTELLIX, Auvelity, SPRAVATO.
Industry payments across UT — which companies pay providers there.
